Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Systemic Lupus Erythematosus
NCT01738360Phase 2Terminated
- Sponsor
- CHU de Nantes
- Start
- Jul 2013
- Primary completion
- Oct 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in systemic lupus erythematosus (SLE), sponsored by CHU de Nantes. Started Jul 2013; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01738360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01738360.